August 2023

Un inhibiteur de JAK pour le traitement de la polyarthrite rhumatoïde : L'expérience du baricitinib

J. Clin. Med. 2023;12(13):4527 doi 10.3390/jcm12134527

This review by Taylor, et al. reviews the long-term safety and efficacy data for baricitinib. Results from several studies showed that baricitinib has greater efficacy and survival compared to TNF inhibitors, and that the rate of CDAI <10 for baricitinib-treated RA patients increased over the course of seven years. Data also showed that remission rates were higher in real-world evidence than in RCTs.

Keywords:

September 2022

Upadacitinib en monothérapie et en association avec des antirhumatismaux modificateurs de la maladie non biologiques dans le traitement du rhumatisme psoriasique

Rheumatology (Oxford) 2022 doi: 10.1093/rheumatology/keab905

In this investigation, upadacitinib showed comparable efficacy as monotherapy and in combination with nbDMARDs in PsA. In coming to this conclusion investigators aimed to assess the efficacy and safety of upadacitinib as monotherapy or in combination with nbDMARDs in patients with PsA.

Keywords:

January 2022

Taux d'incidence des manifestations de pneumopathie interstitielle chez les patients atteints de polyarthrite rhumatoïde traités par tofacitinib

J Clin Rheumatol. 2021;27(8):e482–e490

This post hoc analysis of pooled data from 21 clinical trials in the tofacitinib clinical trial programme highlights the importance of identifying known risk factors of RA-interstitial lung disease (ILD) in clinical practice.Citera, et al. investigated incidence rates of ILD – an extra-articular manifestation of RA – in patients with RA, receiving tofacitinib 5 or 10 mg BID and sort to identify potential risk factors for ILD in these patients....

Keywords:

September 2020

Taux d'Incidence des Pneumopathies Interstitielles Chez les Patients Atteints de Polyarthrite Rhumatoïde Traités au Tofacitinib

Journal of Clinical Rheumatology, Aug 2020 doi: 10.1097/RHU.0000000000001552.

This study highlights the importance of accounting for known risk factors of RA-ILD in clinical practice. Interstitial lung disease (ILD) is an extra-articular manifestation of RA. The post-hoc investigated incidence rates of ILD in patients with RA, receiving tofacitinib 5 or 10 mg twice daily, and identified potential risk factors for ILD. This post-hoc analysis comprised a pooled analysis of patients receiving tofacitinib 5 or 10 mg twice daily or placebo from 21 Phase 1-4, and 2 long-term ex...

Keywords: